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Abstract
The lack of available vaccines against African swine fever virus (ASFV) means that the evaluation of new immunization
strategies is required. Here we show that fusion of the extracellular domain of the ASFV Hemagglutinin (sHA) to p54 and
p30, two immunodominant structural viral antigens, exponentially improved both the humoral and the cellular responses
induced in pigs after DNA immunization. However, immunization with the resulting plasmid (pCMV-sHAPQ) did not confer
protection against lethal challenge with the virulent E75 ASFV-strain. Due to the fact that CD8+ T-cell responses are
emerging as key components for ASFV protection, we designed a new plasmid construct, pCMV-UbsHAPQ, encoding the
three viral determinants above mentioned (sHA, p54 and p30) fused to ubiquitin, aiming to improve Class I antigen
presentation and to enhance the CTL responses induced. As expected, immunization with pCMV-UbsHAPQ induced specific
T-cell responses in the absence of antibodies and, more important, protected a proportion of immunized-pigs from lethal
challenge with ASFV. In contrast with control pigs, survivor animals showed a peak of CD8+ T-cells at day 3 post-infection,
coinciding with the absence of viremia at this time point. Finally, an in silico prediction of CTL peptides has allowed the
identification of two SLA I-restricted 9-mer peptides within the hemagglutinin of the virus, capable of in vitro stimulating
the specific secretion of IFNc when using PBMCs from survivor pigs. Our results confirm the relevance of T-cell responses in
protection against ASF and open new expectations for the future development of more efficient recombinant vaccines
against this disease.
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Introduction
African Swine Fever (ASF) is a fatal hemorrhagic disease of
domestic pigs caused by African Swine Fever Virus (ASFV), the only
member of the family Asfarviridae, a large enveloped virus that
contains a linear double-stranded DNA of 170–190 kbp encoding
more than 150 proteins, many of them involved in virus-host
interactions [1]. The fact that the disease is endemic in many Sub-
Saharan Africa countries and Sardinia, makes this disease a threat
for disease-free countries, as has been demonstrated with the recent
outbreaks declared in Georgia, Russia, Armenia, and Iran [2–4].
Unfortunately, there is no vaccine available for ASFV.
Historical attempts to protect animals with inactivated vaccines
either failed or gave controversial results [5–7]. Studies using
attenuated vaccines demonstrated their potential to protect pigs
against experimental infection with homologous virulent virus but
rarely, against heterologous viruses [8–11]. The main problem
with these attenuated viral strains is due to biosafety issues, since
they retained some virulence and produced sub-clinical infections
in pigs, occasionally becoming chronically infected [12,13].
Little is known about the mechanisms involved in ASF
protection, and most of the experimental evidence dates from
more than a decade ago. Thus, passive transfer experiments have
clearly demonstrated the potential that ASFV antibodies can play
in protection against experimental challenge [14,15]. In conso-
nance with these results, neutralizing antibodies against the
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structural proteins p30, p54 and p72 have been described [16–18].
However, pig immunization experiments using these antigens in
the form of baculovirus-expressed recombinant proteins, yielded
controversial results in terms of the protection afforded against the
ASFV challenge [19,20], most probably due to differences in the
viral strains used.
Together with the protective potential that humoral responses
can afford, new evidence has also demonstrated the role that T-cell
responses can play in protection. Thus, in vivo depletion
experiments, have demonstrated the key role of CD8+-T cells in
the protection afforded by attenuated ASFV strains [21]. The
presence of ASFV-specific cytotoxic T cells during ASFV infection
had been previously demonstrated [22], also identifying p30 and
p73 as potential CTL targets [23,24]. Albeit no records exist about
the protection capability of these specific CTLs in vivo, their
induction might help to explain the partial protection afforded
against ASFV after immunization with baculovirus-expressed
recombinant p54 and p30 proteins [19] and overall, with the
ASFV Hemagglutinin (HA) of ASFV, a protein that conferred
protection in the absence of detectable neutralizing antibodies
[25]. Total baculovirus-infected cell extracts were used as
immunogens in all these experiments, thus increasing the chances
of inducing strong CTL responses, as has been clearly stated for
other viral antigens in the presence of insect-cell debris [26].
In the work presented here we add new evidence about the
relevance of CD8+-T cell responses in protection against ASFV
and demonstrate the potential of DNA immunization to design
safe and efficient future vaccines against ASF. Recent evidence
from our laboratory has demonstrated that DNA vaccines
encoding p30 and p54 fused together (pCMV-PQ) induced good
antibody responses in mice but not in pigs, where they were
undetectable [27]. Here we have extended these studies demon-
strating first, that DNA immunization in pigs could be exponen-
tially improved by adding the extracellular domain of HA (sHA) to
the vaccine-encoded antigens. Pigs immunized with pCMV-
sHAPQ induced strong humoral and cellular responses, even
though no protection was afforded against the lethal ASFV-
challenge. And second that 33% of the pigs (2/6) immunized with
pCMV-UbsHAPQ, encoding the same three ASFV antigens fused
to ubiquitin, survived the lethal challenge. Protection was afforded
in the absence of vaccine-induced antibodies and more impor-
tantly, correlated with the proliferation of antigen specific CD8+
T-cells recognizing two previously undescribed 9-mer epitopes,
both mapping within the sHA. The implications of our results for
the future development of ASFV recombinant vaccines will be
profoundly discussed throughout our manuscript.
Results
Immunoadjuvant potential of the extracellular domain of
the ASF hemagglutinin (sHA) in DNA vaccination
protocols
Aiming to correct the lack of protection afforded by pCMV-PQ, a
DNA vaccine encoding the ASFV p54 and p30 antigens (4), the
extracellular domain of the viral hemagglutinin (sHA) was fused to
the N-terminal end of the p30p54 fusion construct (PQ), thus
obtaining the pCMV-sHAPQ plasmid (Fig. 1). Theoretically,
incorporating sHA should augment the antigenic coverage of our
DNA vaccine formulation [25]. Immunofluorescence experiments
allowed the detection of both p54 and p30 determinants in Vero cells
transfected with pCMV-sHAPQ, showing similar levels and cellular
distribution to those transfected with pCMV-PQ (data not shown).
Once the in vitro expression of both plasmids was confirmed, an
initial in vivo experiment was performed in pigs. Six Landrace X
Large white pigs were immunized with pCMV-sHAPQ while for
comparative analysis a group of 4 pigs were immunized with
pCMV-PQ. An additional group of 4 animals received pCMV as
negative controls for the assay. Four animals from each group
received three DNA-shots at 15-day intervals, and two additional
pigs from the pCMV-sHAPQ group received one extra dose of
DNA (a total of four doses). All fourteen pigs were bled 15-days
after each injection to analyze the specific antibodies induced by
ELISA and/or western-blotting. In contrast with the lack of
response induced by pCMV and pCMV-PQ, every single pig
immunized with pCMV-sHAPQ showed detectable specific
antibody responses against p30, reaching a plateau after the third
injection (Fig. 2A). An additional boost (fourth DNA injection) did
not seem to improve the level of antibodies induced (Fig. 2B).
Specific antibodies against p54 were also detectable in the serum
of each pig immunized with pCMV-sHAPQ, following exactly the
same kinetics as the anti-p30 antibodies and reaching their
maximum level after the third immunization, as shown by
western-blotting using ASFV extracts (Fig. 2C). No responses
were detectable against HA (data not shown).
Immunization with pCMV-sHAPQ also induced specific T-cell
responses in every single pig, detectable by IFNc-ELISPOT after
in vitro stimulation with either live-ASFV or with the specific
recombinant proteins. PBMCs obtained 15 days after each
immunization with pCMV-sHAPQ showed detectable IFNc-
secretory T-cells after in vitro stimulation with ASFV (Fig. 3). As
occurred for the antibody responses, no responses were detectable
against HA, the specificity of the T-cell responses being limited to
p30 and p54 (Fig. 3). As with the humoral responses, no boosting
effect was observed for the T-cell responses induced between the
third and the fourth vaccine dose (Fig. 3). The lack of responses
observed with pCMV-PQ confirmed recent results obtained in our
laboratory [27], demonstrating the potential adjuvant properties of
the ASFV sHA.
pCMV-sHAPQ does not protect pigs from ASFV lethal
challenge
To evaluate the protective potential of pCMV-sHAPQ, the four
pigs immunized with three doses of this plasmid (pig numbers 9 to
12), were infected with 104 UHA50 of the E75 virulent strain. The
groups of pigs immunized with either pCMV or pCMV-PQ were
used as controls for the assay. Clinical signs of ASF were monitored
daily and pigs were bled every other day to follow viremia.
Despite the good humoral and cellular responses induced after
vaccination with pCMV-sHAPQ, immunized animals showed
similar ASF clinical signs to pCMV and pCMV-PQ pigs, all dying
between days 6 and 8 post-infection (p.i.) (Fig. 4A), showing post-
mortem lesions typical of acute ASFV infections indistinguishable
from the other groups. In agreement with these findings, the three
groups of pigs showed similar viremia kinetics and almost identical
virus titres at each time-point p.i. tested (Fig. 4B) in two separate
experiments. Lack of protection correlated with the inability of the
sera from the pCMV-sHAPQ immunized pigs to neutralize ASFV
infection (data not shown).
DNA vaccination ‘‘a la carte’’: avoiding the humoral
response
To avoid the induction of antibody responses, we decided to
design a new plasmid, encoding the three ASFV antigens: p54,
p30 and sHA, fused to ubiquitin (pCMV-UbsHAPQ; Fig. 1); a
strategy designed to enhance the CTL responses while avoiding
the induction of antibodies. In contrast to the correct in vitro
expression of the antigens encoded by either pCMV-PQ or
DNA Vaccination against ASFV in Pigs
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Figure 1. Schematic representation of the plasmids used for immunization and ASFV antigens by them encoded.
doi:10.1371/journal.pone.0040942.g001
Figure 2. pCMV-sHAPQ induces specific antibody responses in pigs. 14 pigs were divided into three groups receiving either: the pCMV-
sHAPQ plasmid (6 pigs), the pCMV-PQ plasmid (4 pigs) or the pCMV empty plasmid as controls for the assay (4 pigs). Four pigs from each group were
immunized three times and two extra pigs from the pCMV-sHAPQ immunized-group received a fourth dose of this same plasmid. (A) Sera collected
15 days after each DNA vaccine administration were used to follow by ELISA the kinetics of the specific anti-p30 antibodies induced after DNA
immunization. (B) Sera collected 15 days after the last DNA vaccination was used to ELISA-titrate the anti-p30 antibodies induced. Data shown
correspond to average O.D values and standard deviations obtained per each immunization group. (C) Confirmatory Western-blot using ASFV
infected cell extracts as antigen. Immunoreactive bands correspond to the specific recognition of the immunodominant p30 protein (arrow) and to
the diverse p54 isoforms (arrow head) found in these extracts, ranging the last ones between 22 and 27 KD [65,66]. Figure shown corresponds to the
results obtained with a representative serum (1:100 dilution) obtained 15 days after the third immunization with pCMV (a), pCMV-PQ (b) or pCMV-
sHAPQ (c). The anti-p30 monoclonal antibody (d) and the specific polyclonal anti-p54 antibody (e) confirm the specificity of the reactions.
doi:10.1371/journal.pone.0040942.g002
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pCMV-sHAPQ, no expression was detected after transfection with
pCMV-UbsHAPQ, unless cells were treated with the MG132
proteasome inhibitor (data not shown). Once the in vitro targeting
of the ubiquitinated construct to the proteasome and its efficient
degradation were demonstrated, a second set of in vivo
experiments was performed. On this occasion, twelve Landrace
X Large white pigs were immunized with pCMV-UbsHAPQ and
four extra-pigs were immunized with the empty plasmid (pCMV)
as controls for the assay. Half of the animals of each group (six pigs
with pCMV-UbsHAPQ and two with pCMV) were immunized
twice while the other half were immunized four times with the
corresponding plasmids.
As expected, pigs immunized with pCMV-UbsHAPQ showed
no detectable antibody responses against either p30 or p54 (data
not shown). The lack of antibody induction might represent the in
vivo reflection of the successful degradation of the ubiquitinated
ASFV proteins, as has previously been described for other antigens
[28].
Albeit qualitatively similar, the magnitude of the IFNcrespon-
sesinduced by pCMV-UbsHAPQ seemed to be lower by ELI-
SPOT than those obtained with pCMV-sHAPQ. This was
particularly evident after in vitro stimulation with a mixture of
the recombinant proteins or individually with the specific p30 and
p54 proteins (compare figures 3 and 5A). As described for the
pCMV-sHAPQ immunized animals, no specific stimulation was
found in response to the recombinant HA protein (Fig. 5A).
However, all pigs showed relatively high levels of specific T-cells
capable of secreting IFNcin response to in vitro stimulation with
ASFV (Fig. 5A). As had occurred with pCMV-sHAPQ, no
boosting effect was evident.
pCMV-UbsHAPQ confers partial protection against ASFV
challenge
In contrast to the rest of the DNA-constructs tested to date in
our laboratory, a proportion of the pigs immunized with pCMV-
Figure 3. pCMV-sHAPQ induces specific T-cell responses in pigs. PBMCs obtained before ASFV challenge from pigs immunized with pCMV,
pCMV-PQ or pCMV-sHAPQ (immunized three or four times), were in vitro stimulated with media (negative control), with the E75 ASFV isolate (105
HAU50/ml), with a mix of the p54, p30 and HA ASFV proteins (6 mg/ml of each one) or with each one of these proteins individually. Values shown
correspond to the average number of IFNc-secretory cells detected per million of PBMCs. Standard deviations found within each group are also
represented.
doi:10.1371/journal.pone.0040942.g003
Figure 4. pCMV-sHAPQ does not protect against lethal ASFV
challenge. (A) Surviving kinetics of pCMV, pCMV-pCMV-PQ and pCMV-
sHAPQ immunized pigs after lethal challenge with ASFV (104 UHA of the
E75 isolate). (B) Viremia kinetics of these same individuals after ASFV
challenge (days 3, 5 and 7 post infection). Results are represented as the
logarithm of HAU50/ml serum (mean and standard deviation from each
group are shown).
doi:10.1371/journal.pone.0040942.g004
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UbsHAPQ survived the lethal challenge with ASFV. A total of
three pigs survived the lethal challenge: 2 out of 6 (33%)
immunized twice with pCMV-UbsHAPQ and 1 out of 6 in the
group receiving four plasmid doses (Fig. 5B). As expected, control
animals (pCMV group) died between days 7 and 8 post-challenge,
following the typical ASF course, while in clear contrast, only 2 out
of 12 pigs, immunized with pCMV-UbsHAPQ (one per group)
died at day 8pi. By day 10 p.i. more than 50% of the pigs
immunized with pCMV-UbsHAPQ were still alive (a fact never
observed in naı¨ve pigs challenged with this viral dose) and by
day 12, the general body condition of surviving pigs had rapidly
improved, including fever (data not shown). By the end of the
experiment, at day 25 p.i. survivor pigs were totally recovered, not
showing clinical signs of ASF, nor viremia. Confirming these
results, no virus was detectable in any of the tissues tested,
including spleen, tonsils and retropharingeal lymphnodes. As
expected, high viral loads (ranging between 106 and 108 HAU50/
gr of tissue) were found in those same organs in control animals at
the time of necropsy. Interestingly, surviving pigs showed no virus
at day 3 p.i., a time at which the rest of the animals showed high
viremia titres (Fig. 6). The in vivo significance of the survival
results was statistically confirmed. Thus, both groups immunized
with pCMV-UbsHAPQ showed statistically significant differences
when compared with the control group (p = 0.0068), while no
significant differences were found between the groups receiving
two or four doses of the pCMV-UbsHAPQ plasmid (p = 0.7418).
Confirming the absence of specific B-cell priming, pCMV-
UbsHAPQ-immunized pigs did not show any detectable boosting
effect on the specific antibody responses induced after ASFV
challenge, showing indistinguishable antibody-kinetics from con-
trol animals after ASFV infection (not shown).
Protection correlates with the expansion of ASFV-specific
CD8+ T-cells: identification of two immunodominant
epitopes within the ASFV HA
As represented in Figure 7A, control animals showed the
characteristic ASFV-leukopenia as soon as three days after
challenge, with the number of cells in blood dropping below 106
cells/ml from day 5 after infection, they were incapable of
recovery and finally died between days 7 and 8 p.i. In contrast,
Figure 5. pCMV-UbsHAPQ protects against lethal ASFV challenge. (A) PBMCs from pigs immunized twice (2x) or 4 times (4x) with pCMV-
UbsHAPQ or with pCMV, were in vitro stimulated with media (negative control), with the E75 ASFV isolate (105 HAU50/ml), with a mix of the p54, p30
and HA ASFV proteins (6 mg/ml of each one) or with each one of these proteins individually. Values shown for each immunization group correspond
to the average number of specific IFNc-secretory cells detected per million PBMCs. Standard deviations found within each group are also
represented. (B) Immunized pigs were challenged with a lethal dose of ASFV (104 UHA of the E75 isolate) and survival record were plotted. Groups
immunized with pCMV-UbsHAPQ showed statistically significant differences (*) when compared with the control group (p = 0.0068).
doi:10.1371/journal.pone.0040942.g005
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surviving pigs showed a clear delay in the appearance of
leukopenia, even showing a higher number of cells in blood by
day 3 p.i. (Fig. 7A), coinciding with the lack of virus at this time
point (Fig. 6). Surviving pigs, however, suffered a dramatic drop in
the total number of cells by day 5 p.i., initiating their recovery and
finally stabilizing cell counts (Fig. 7A). Cell surface staining showed
almost identical kinetics for the CD8+ T-cell subset (Fig. 7B). None
of the rest of the cell subsets analysed (CD4+ T-cells, SW172a+
cells or CD163+ cell) showed such significant variations in their cell
numbers during the ASFV infection (data not shown), therefore
allowing us to focus our work on identifying the specificity of the
expanded CD8+ T-cells.
These findings encouraged us to focus our efforts towards the
theoretical prediction of CD8+ T-peptides within the vaccine-
encoded antigens. A panel of 53 9-mer peptides selected in silico
from within the p54 (5), p30 (18) and sHA (30) protein sequences,
according to their theoretical potential as CTL epitopes (details in
Materials and Methods), were tested by IFNc-ELISPOT. From all
the peptides tested, only two were capable of specifically
stimulating PBMCs from survivor pigs to secrete IFNc, both
belonging to the ASFV HA: the F3 peptide (SVDSPTITY;
positions 116 to 124 of HA) and the A6 peptide (TNGDILNYY;
positions 155 to 163 of HA). An immunodominance hierarchy
seemed to exist in the responses induced. Two of the three survivor
pigs (pigs 6 and 9) mainly responded against the F3 peptide and
more weakly against the A6 peptide, while the third survivor
showed dominant responses against the A6 peptide and subdom-
inant responses against the F3 peptides (Fig. 8). Confirming their
immunostimulatory capability, SLAI+/SLAII2 skin fibroblasts
derived from surviving pigs were very efficient at presenting F3
and A6 peptides to their autologous PBMCs (Fig. 8).
Discussion
Fifty years after first entering the Iberian peninsula from
Western Africa [29], ASFV has emerged again as real threat both
for European and Asian countries, due to the ASFV outbreaks first
declared in Georgia 2007 [2], this time imported from Eastern
Africa [3,30,31]. In spite of the relatively profound knowledge that
exists about some relevant aspects of ASFV biology, there is no
vaccine available, and no effective treatment against ASF.
Therefore, the control of ASF relies on its efficient diagnosis and
the subsequent culling of infected animals, measures unadoptable
in poor endemic African countries.
Little is known about the immunological mechanisms involved
in protection against this complex virus, and even less about
potential vaccine targets. Since original attempts of vaccination
against ASFV, based on live attenuated and inactivated viruses
were not very satisfactory [5,12], few vaccine prototypes have been
experimentally tested in vivo. Targeted disruption of specific genes
such as those encoding proteins involved in evading host defence
might yield promising results for the future development of safer
and efficient recombinant-live attenuated vaccines. Despite the
fact that this technology has been successfully used to characterize
relevant ASFV virulence factors in vivo [32–37], to date no further
evidence has been presented about the use of recombinant viruses
obtained for vaccine purposes, most probably due to the residual
virulence they retain [12,13]. Besides these attempts, few
approaches have been used to identify potential targets to develop
subunit vaccines, most have been based on their antigenic
Figure 6. Surviving pigs show a delay in the viremia onset and
clear the virus by day 25 post-infection. Pigs immunized with
pCMV-UbsHAPQ, either twice (A) or four times (B) were infected with
104 UHA of the E75 isolate and blood samples were taken serially at
days 3, 5, 7, 9, 12, 15, 20 and 25 to follow the viremia kinetics. Individual
results are represented as the logarithm of HAU50/ml serum, while
mean and standard deviation values are represented in both panels for
the pCMV-immunized control group.
doi:10.1371/journal.pone.0040942.g006
Figure 7. Surviving pigs show a rapid recovery from the ASFV-
provoked leukopenia and a dramatic expansion of CD8+ T-
cells. (A) Total nucleated-cell counting using whole blood samples
taken at different days after ASFV challenge. (B) Number of CD8+ T-cells
found at different times post-infection from these same blood samples
after PBMC separation and CD8+ surface specific staining using the
specific anti-CD8 monoclonal antibody. Values represented in both
panels correspond to the average number of cell per mm3 of pig blood.
Standard deviation shown corresponds to those found within the
pCMV-control group (dashed line) and those found for the three
surviving pigs, pre-immunized pCMV-UbsHAPQ (solid line). No signif-
icant differences were observed in the cell counts (nor in the total, nor
the specific CD8+ T-cell counts), between non-surviving pigs, indepen-
dent of the DNA plasmid used.
doi:10.1371/journal.pone.0040942.g007
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properties that have not however succeeded in inducing protection
[38] or have induced partial protection against ASFV challenge
[25,39]. Our first attempts to induce a protective immune
response against ASFV with DNA vaccines encoding two of these
antigens (p54 and p30) in the form of the chimeric protein (PQ)
totally failed [27]. Here, we have extended these studies by
incorporating the extracellular domain of the ASFV haemagluti-
nin (sHA) to our vaccine formulation, aiming to augment the
antigenic coverage of our DNA vaccine [25]. Addition of sHA
dramatically improved both the humoral and the cellular
responses induced against the fused antigens: p54 and p30,
reaching optimal results after three intramuscular injections. The
sequence similarity between sHA and the CD2 leukocyte molecule
[40,41] allowed speculation about its capability to target the
antigens to cells expressing the CD2 receptors CD48 and CD58
[42–44], such as Antigen Presenting Cells (APCs). Therefore, the
improvement of the immune responses induced by the sHA fusion
could be the result of antigens targeting to the APCs. Antigen
targeting has proven to be successful in many other systems
[45,46], and similar results were obtained by targeting these ASFV
antigens with a single chain antibody (ScFv) recognizing the SLA
II molecules [27]. Further work should be done to definitively
demonstrate if fusion of sHA to antigens results in targeting to cells
expressing the CD2 ligands, and the relevance of such targeting in
the immune responses induced. The improvement of the immune
responses induced by incorporating sHA might also be due to the
potential presence of T-helper cell epitopes in this molecule.
Unfortunately enough, in vitro stimulation with the full-length HA
did not allow confirming this hypothesis. Further work should be
done in the future on this direction.
Despite the good immune response obtained after immuniza-
tion with pCMV-sHAPQ, pigs were not protected from lethal
challenge, showing undistinguishable ASF clinical signs and
viremia kinetics from control animals. Lack of protection
coincided with the induction of specific antibodies that, however,
did not neutralize ASFV infection in vitro, an activity which had
been previously associated with in vivo protection [19,47]. This
data seems to confirm very recent results obtained in our
laboratory, showing the inability of DNA vaccines to induce
neutralizing antibodies against ASFV p30 and p54 proteins that
conversely, might even exacerbate ASFV infection [27]. Besides
the potential adjuvant effect of sHA, currently being explored to
improve the immune responses induced against other antigens in
pigs (PCT/ES2008/000264), the results obtained after immuni-
zation with pCMV-sHAPQ were by itself extremely informative
from the scientific point of view, as later demonstrated with the
protection afforded with pCMV-UbsHAPQ, a new plasmid
construct encoding exactly the same ASFV determinants.
Aiming to avoid the induction of undesired antibodies and to
improve the specific CD8-T cell responses, a new vaccine was
designed, pCMV-UbsHAPQ, encoding exactly the same antigenic
determinants: p54, p30 and sHA, fused to the cellular polypeptide
ubiquitin. As expected [28], vaccination with pCMV-UbsHAPQ
did not induced antibody responses in pigs but conferred partial
protection against ASFV challenge, confirming the relevance of T-
cell responses in protection against ASFV. Our approach, far from
being obvious, allowed the dissection of the role that CD8+ T-cell
responses could play in the protection afforded by our DNA
vaccine against ASFV in its domestic host, an almost neglected
issue in the specialized literature. The work done by Oura et al
(41) is in our understanding, the only study clearly demonstrating
the relevance of CD8+ T-cells in the protection afforded by
attenuated ASFV viruses, albeit the specificity of such CD8+ T-
cells has never been described. Our results not only confirm and
extend these studies to the field of DNA vaccines but also identify
for the first time, some of these potentially protective CD8+ T-cell
epitopes from within the sHA ASFV antigen. The protection
afforded was not improved by increasing the number of DNA-
vaccine doses, probably reflecting the lack of boosting effect for the
T-cell responses induced after one boost. Conversely, we found
that 2 out of 6 pigs that received 2x doses of pCMV-UbsHAPQ
survived (33%) while only 16% of the pigs that received 4x plasmid
doses survived. Although not statistically significant, the same
results were obtained in two separate experiments, indicating that
multiple boosting could be somehow deleterious in terms of the
protection afforded. Of the possible factors contributing to the
Figure 8. Identification of protective SLAI restricted 9-mer T-cell peptides. PBMCs from surviving pigs, pre-immunized with pCMV-
UbsHAPQ (obtained at day 25 after ASFV lethal challenge), were in vitro stimulated with 53 9-mer peptides predicted as potential CTL epitopes. Data
represented in grey boxes corresponds to the specific responses found for the two individual sHA epitopes: F3, and A6. Data represented in open
boxes corresponds to the values obtained after in vitro stimulation with peptide-coated autologous SLAI+/SLAII2 skin fibroblasts.
doi:10.1371/journal.pone.0040942.g008
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inconsistencies in the relatively low protection conferred by this
vaccine, we hypothesize that immunization with 4x doses of
pCMV-UbsHAPQ might be able to induce low levels of non-
neutralizing and exacerbating antibodies [27] that in turn, could
counteract the protective effects of the specific CD8-T cells
induced by the vaccine. Albeit undetectable by our methodology,
we should not rule-out this possibility. Previous results obtained in
the lab using the mouse model seemed to confirm this hypothesis
since a few mice immunized with 4x dosed of pCMV-sHAPQ
developed low, albeit significant specific antibody levels. Addi-
tionally, prime-boost regimes priming with 2x doses of pCMV-
UbsHAPQ and boosting with heterologous expression systems
encoding the full length sHAPQ (without ubiquitin), did not confer
protection against ASF-challenge, correlating with the induction of
non-neutralizing antibodies (unpublished results).
Despite the fact that pCMV-UbsHAPQ induced qualitatively
similar T-cell responses to pCMV-sHAPQ after in vitro stimula-
tion with ASFV, p54 or p30 (no responses were ever detected after
stimulation with HA), the magnitude of these responses seemed
overall to be quantitatively lower for the former when using the
recombinant proteins (compare figures 3 and 5 A), most probably
reflecting an immunological bias of the immune responses induced
by the ubiquitinated construct towards the induction of peptide-
specific CD8+ T-cell responses. This theory was definitively
confirmed by demonstrating the potential of the PBMCs from
pigs that survived after pCMV-UbsHAPQ immunization, to
efficiently secrete IFNc after in vitro stimulation either with the
synthetic soluble peptides (F3 and A6) or with autologous peptide-
coated fibroblasts. Lack of available specific peptides at the time of
performing the in vivo experiment 1 did not allow the
performance of in vitro-peptide stimulation experiments with
PBMCs from pCMV-sHAPQ pigs. However, today we know that
the main source of IFNcexpressed by PBMCs from pigs
immunized with pCMV-sHAPQ was a subset of specific CD4+
T-cells that specifically proliferated in response to 5-day-stimula-
tion with p30 and p54 protein but did not respond to the addition
of the 9-mer sHA peptides. Conversely, a specific expansion of
CD8+ T-cells was observed when stimulating PBMCs from the
pCMV-UbsHAPQ immunized pigs with the specific sHA
peptides, confirming their SLAI restriction (manuscript in
preparation).
Interestingly, the two SLA I-restricted epitopes identified, from
the 53 predicted in silico, mapped within the sHA. The fact that
none of them mapped within the p54, nor the p30, a protein
previously described as a potential CTL target [24], might help to
explain the lack of protection afforded by DNA vaccines encoding
exclusively p54 and p30 [27]. Confirming this theory, the non-
protective pCMV-sHAPQ plasmid was only capable of inducing
responses against p54 and p30, while no responses were detectable
against HA, nor the sHA peptides (data not shown).
Prediction of peptide-MHC I binding is the main basis for the
anticipation of CTL epitopes [48,49]. However, polymorphism of
pig MHC I molecules (SLA I) with few known SLA I restricted
epitopes hinders the prediction of CTL epitopes by their binding
to SLA I. Therefore, we used an alternative approach based on
their binding affinity to the transporters associated with antigen
processing (TAPs), molecules which shuttle the peptides from the
cytosol to the endoplasmic reticulum to be presented by MHCI
molecules. Although the TAP-binding affinity model used here
was initially designed for human predictions [50,51], computa-
tional evidence suggests that the model could be applied to
mammals in general. Lack of detectable specific IFNc-responses
after PBMCs stimulation with any of the other 51 synthesized
peptides might highlight: limitations in our theoretical predictions,
technical limitations of our read-out assays, the establishment of
immunodominance hierarchies masking subdominant responses
or the absence of other CTL epitopes with protective potential
within p54, p30 and sHA, at least to be presented in the SLA I
context of the pigs used in this study. Peptide immunization
experiments using either conventional pigs or specific pathogen
free (SPF) pigs (manuscript in preparation), seems to confirm the
protective potential of the F3 and A6 CTL peptides in a
proportion of pigs that varied between 20–33% of the animals,
pointing toward a SLA I-restricted protection. We are currently
haplotyping the surviving pigs from these and other experiments
being performed with other viral determinants aiming to confirm
this hypothesis; a long term objective, since haplotyping domestic
pigs it is not an easy task, even for laboratories exclusively working
on this issue.
In summary, the results presented in this work demonstrate not
only the potential of DNA immunization as a strategy to design
future ASFV vaccine candidates, but also confirm the importance
of the vaccine-induced CD8+ T-cell responses against ASFV and
identifies for the first time two SLA I-restricted CD8+ T-cell
epitopes with putative protective potential. We believe that the
future development of an effective vaccine against such a complex
virus will need the induction of both, broader CTL responses
covering the SLA I-heterogeneous swine population and neutral-
izing antibodies. We are currently addressing these goals following
two different approaches: on one hand, we are attempting to
identify as many CTL epitopes as possible within the ASFV
polypeptides by using ELI libraries [52] developed in the
laboratory from the entire ASFV genome (manuscript in
preparation) and on the other hand, we are attempting to obtain
broader and optimal cellular and humoral responses concomi-
tantly by testing several strategies of proved efficacy also in
Veterinary Medicine, including: electroporation to improve DNA
vaccine delivery [53]; the use of co-stimulatory molecules such as
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated
CpG motifs [54]; and ‘‘prime-boosting’’ strategies [55,56].
Materials and Methods
Ethics Statement
All experiments were performed in the Biosafety Level 3
facilities of the Centre de Recerca en Sanitat Animal (CReSA-
Barcelona). Animal care and procedures were performed in
accordance with the guidelines of the Good Experimental
Practices (GEP) and under the supervision of the Ethical and
Animal Welfare Committee of the Universitat Auto`noma de
Barcelona (UAB; Permit Number: DMAH-5796). Animals were
observed daily according to a welfare schedule in order to monitor
their health status, and check list (approved by the CRESA Animal
Welfare Committee) to monitor the clinical aspects after the
infection with ASFV.
Plasmid construction
The open reading frame (ORF) encoding the extracellular
domain of the ASFV hemagglutinin (sHA) from the Spanish
isolate E75 was obtained by PCR using the forward (59-
GCGGCCGCCATGTGGAGTACTTTAAATCAAAC-39) and
reverse (59-CGGCCGAGATCTTGTGGATAAATAATTTTG-
39) primers and the pBakpak-HA plasmid [25] as template. The
amplified fragment was cloned in the unique NotI cloning site of
pCMV plasmid (Clontech) to obtain pCMV-sHA with a BglII
unique site at the 39-end for further cloning purposes.
The ORF encoding PQ, a chimeric fusion of the ASFV p30 and
p54, also from the Spanish isolate E75 was PCR amplified using
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the forward (59-GGATCCATGGATTCTGAATTTTTT-
CAACCGG-39) and reverse (59-AGATCTTACAAG-
GAGTTTTCTAGGTC-39) primers and the pCMV-PQ plasmid
[27], as template. The amplified fragment was digested with the
BamHI and BglII restriction enzymes and cloned into the unique
BglII cloning site of pCMV-sHA to obtain the pCMV-sHAPQ
plasmid, encoding PQ in frame with the ASFV sHA polypeptide.
Finally, the ORF encoding sHAPQ was PCR amplified using
the forward (59-GGATCCATGTGGAGTACTTTAAAT-
CAAAC-39) and reverse (59-AGATCTTACAAGGAGTTTTC-
TAGGTC-39) primers containing the BamHI and BglII restriction
sites and the newly generated pCMV-sHAPQ plasmid as PCR-
template. The amplified fragment was cloned using the BglII site of
pCMV F1/2 Ubiq plasmid [57], to obtain the plasmid pCMV-
UbsHAPQ, encoding sHAPQ fused to cellular ubiquitin.
All the products were expressed under the control of the
immediate early promoter of human cytomegalovirus.
A schematic representation of the plasmids used throughout this
work is provided (Fig. 1). In order to facilitate the comprehension
of the results obtained, the specific ASFV products encoded by
each vaccine (if any) are also indicated.
Immunization of animals and in vivo experimental design
Experiments with 8-week-old Landrace X Large white pigs
were always performed under the approval of the Ethical and
Animal Welfare Committee of the Universitat Auto`noma de
Barcelona and infections with ASFV were done under BioSecurity
level 3 (BSL-3) conditions at CReSA. DNA immunization
experiments (experiments 1 and 2) were performed using different
numbers of doses (600 mg of DNA each) of the corresponding
endotoxin-free DNA plasmid (Qiagen), administered at 15 day
intervals. One third of each vaccine dose was injected in the rectus
femoris quadriceps muscle, one third in the trapezius muscle of the
neck and the last third was subcutaneously injected in the ear.
Experiments were repeated twice to ensure the reproducibility of
the results.
In vivo experiment 1. 14 pigs were divided into three groups
receiving either: the pCMV-sHAPQ plasmid (6 pigs), the pCMV-
PQ plasmid (4 pigs) or the pCMV empty plasmid as controls for
the assay (4 pigs).
In vivo experiment 2. 16 pigs were divided into three groups
receiving either: the control pCMV plasmid (4 pigs), the pCMV-
UbsHAPQ plasmid twice (6 pigs) or the pCMV-UbsHAPQ
plasmid four times (6 pigs).
Antibody detection
ASFV specific antibodies in pig sera were detected by
conventional ELISA assay to detect specific antibodies against
either whole ASFV or the p30 structural protein, as previously
described [58]. To confirm the positive results, sera were tested by
western blot assay using crude protein extracts obtained either
from Thriclopusia ni larvae infected with a recombinant baculovirus
expressing the ASFV p54 protein [59], the ASFV HA [25] or from
ASFV infected Vero cell supernatants processed as previously
described [60]. Samples were run on 4–20% Tris-glycine SDS-
polyacrylamide gels (Novex) followed by transfer to nitrocellulose
filters (Bio-Rad). Next, membranes were cut and divided into
4 mm wide strips, blocked with 2% non-fat milk and then tested
with individual sera diluted 1:100 in PBS-milk. Finally, the
presence of immunocomplexes was detected using either a
peroxidase-labeled goat anti-mouse IgG antibody or a peroxi-
dase-labeled mouse anti-pig IgG antibody (Sigma). Colorimetric
detection was achieved by using 4-Chloronaphtol as substrate
(Sigma). Albeit antibodies against p30 and p54 are detectable both
by ELISA and by Western blotting, the sensitivity of the
techniques change for each one of these ASFV antigens, the latter
being ideal to specifically evaluate the induction of anti-p54
antibodies [59].
The detection of neutralizing antibodies was performed as
previously described [61]. Briefly, 10 fold serial dilutions of the
E75 ASFV strain (starting with 105 hemadsorbing units (HAU50),
were mixed (1:2) with the corresponding inactivated pig serum.
After a 1 h incubation at 37uC in a 96-well plate, 46105
pulmonary alveolar macrophages (PAMs) were added to each well
and cultured for 24 hours, before adding porcine erythrocytes
(diluted 1/100). To follow the appearance of hemadsorption,
plates were observed every 12 hours. As a control for the assay,
hyperimmune serum from a pig that had recovered from an ASFV
infection was used.
Theoretical prediction of CTL epitopes
In silico prediction of CTL epitopes was based on their binding
affinity to TAP using a support vector machine regression model
[50] that was extended to account for the fact that MHCI-
restricted epitopes can often be transported by TAP as N-
terminally elongated peptide precursors [51]. Following this
method, we designed 53 9-mer peptides from the antigens
encoded within pCMV-UbsHAPQ, corresponding with the ASFV
proteins: p54, p30 and sHA. These peptides were individually used
as stimulators in IFNc-ELISPOT assays.
Swine IFNc-ELISPOT
Peripheral blood mononuclear cells (PBMC) were separated
from whole blood by density-gradient centrifugation with
Histopaque 1077 (Sigma). For PBMC cultures, RPMI 1640
medium supplemented with 10% foetal calf serum (Invitrogen),
50,000I U penicillin/l (Invitrogen) and 50 mg streptomycin/l
(Invitrogen) was used. Trypan blue was used to assess cell-viability.
The frequency of ASFV-specific IFNc-secreting cells (IFNc-SC) in
PBMC were analysed by an ELISPOT assay using commercial
mAbs (Swine IFNc Cytoset; Biosource Europe) following a
previously reported method [62]. Briefly, 96-well plates (Costar
3590; Corning) were coated overnight with 8.3 mg/ml of IFNc
capture antibody diluted in carbonate/bicarbonate buffer (pH9.6).
Plates were then washed and blocked for 1 h at 37uC with 150 ml
PBS with 0.5% BSA. Once the blocking solution was eliminated,
56105 PBMCs were dispensed per well and cultured with the
appropriate stimulus: ASFV E75 isolate was used at 106 HAU50/
ml, baculovirus-expressed p30, p54 and HA proteins were used at
6 mg/ml (a baculovirus expressing an irrelevant protein was used
as control), and peptides from p30, p54 and HA proteins were
used at 1 mg/ml. After a 20 h incubation at 37uC in a 5% CO2
atmosphere, cells were removed and the biotinylated detection
antibody was added at 2.5 mg/ml and incubated for 1 h at 37uC.
The reaction was revealed by sequential incubation of plates with
streptavidin–peroxidase (1 h) and insoluble 3,39,5,59-Tetramethyl-
benzidine (TMB; Calbiochem). Unstimulated cells and phyto-
haemagglutinin (PHA)-stimulated controls (5 mg/ml) were also
included. To calculate the ASFV-specific frequencies of IFNc-
secreting cells, counts of spots in unstimulated wells were
subtracted from counts in virus-stimulated wells. The frequency
of cytokine-producing cells was expressed as responding cells in
106 PBMC.
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Swine fibroblast isolation and characterization as antigen
presenting cells
Fibroblasts were obtained from the skin of survivor pigs
following previously described protocols [63], with slight modifi-
cations. Briefly, 2 cm2 segments of skin were obtained from
previously razed and chlorexidine-disinfected skin and immedi-
ately included in 0.5% Trypsin in PBS. After O/N incubation at
4uC, skin fragments were cultured in RPMI supplemented with
10% FCS. Primary fibroblast maintained their viability after
multiple serial passages, retaining their capacity to present the
SLAI-restricted 9-mer ASFV peptides to their autologous PBMCs
in an IFNc – ELISPOT assay. Briefly, fibroblasts were incubated
in vitro for 1 h at 37uC with or without the specific peptides and
after several washes, they were added as stimulators of their
autologous PBMCs at 1:10 ratio for 20 h and then the ELISPOT
assay was continued as described above.
Virus and challenge
All pigs were challenged intramuscularly with 104 HAU50 of the
highly virulent E75 ASFV isolate. Lethality was recorded as the
gold standard marker of protection, since non-protected pigs
should always succumb before day 9 post-infection due to the high
lethal dose administered (.20 LD50s). Additionally, clinical signs
of ASF (fever, anorexia, lethargy, shivering, cyanosis and
recumbency) were monitored daily.
Blood samples were collected before and at different times after
virus challenge for detection of viremia. The virus was titrated in
porcine alveolar macrophages by a hemoadsorption assay. Briefly,
serial dilutions of sera were incubated with 46105 porcine alveolar
macrophages in each well. After 24 h porcine erythrocytes (whole
blood diluted 1:100 in PBS) were added to each well. After 12 h
and every 24 h the plates were observed to follow the
hemoadsorption effect. Titres were calculated and expressed as
HAU50/ml.
Leukopenia due to ASFV infection was followed by counting
the number of cells/ml of blood (1/100 diluted blood mixed 1:1
with Turks solution) and also by flow cytometry using the diverse
surface-cell markers described below.
Flow cytometry
Surface PBMCs staining was performed as previously described
[64], monoclonal antibodies against CD4 (74-12-4 clone), CD8
(76-2-11 clone), CD163 (2H12/BM clone) and SWC3 (BL1H7
clone) were used. Hybridoma supernatants (generously provided
by J. Dominguez) were used diluted 1:5 and secondary FITC
conjugated anti-isotype antibodies (Vitro SA) were used at a
dilution of 1:100. Cell phenotypes were analyzed by flow
cytometry (BD FACSaria I).
Additionally, surface expression of SLA I and SLA II molecules
was also analyzed using primary isolated fibroblasts and mono-
clonal antibodies BL6H4 (anti-SLA I) and 1F12 (anti SLA II-DR),
respectively, followed by an incubation with the corresponding
FITC conjugated anti-isotype antibodies (Vitro SA).
Statistical analysis
Survival data was subjected to the Logrank test of the Kaplan-
Meier survival curves using the NCSS-PASS software.
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